Filing Flows

Filing Flows › Companies › Xenon Pharmaceuticals › Cash flow

Xenon Pharmaceuticals cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$95.7M in Q2 2026 · −$339M over twelve months

Operating cash flow−$95.4M
Capital spending−$275K
Free cash flow−$95.7M

Analysis

In Q2 2026, Xenon Pharmaceuticals generated −$95.4M of operating cash flow and spent $275K on capital projects, leaving free cash flow of −$95.7M. That is $31.3M less than in Q2 2025 (−$64.4M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$338M; the largest uses were other investing ($636M), operating cash flow ($338M), capital spending ($1.0M); besides operations, cash came from other financing ($950M), shares issued ($9.3M); the cash balance fell by $15.9M.

Operating cash flow was −$95.4M against net income of −$111M. The largest differences: stock-based pay +$16.7M, payables +$5.7M, prepaid and other assets −$2.5M.

Free cash flow

Xenon Pharmaceuticals: free cash flow by quarterXenon Pharmaceuticals: free cash flow by quarter−$50.3MQ3 2024−$55.2MQ4 2024−$61.7MQ1 2025−$64.4MQ2 2025−$72.0MQ3 2025−$81.8MQ4 2025−$89.0MQ1 2026−$95.7MQ2 2026
Operating cash flow less capital spending.
Xenon Pharmaceuticals: operating cash flow against capital spendingXenon Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending−$49.7M$590KQ3 2024−$54.4M$783KQ4 2024−$61.7M$43KQ1 2025−$64.2M$157KQ2 2025−$71.8M$281KQ3 2025−$81.5M$318KQ4 2025−$88.9M$133KQ1 2026−$95.4M$275KQ2 2026
Latest (Q2 2026): Operating cash flow −$95.4M, Capital spending $275K.

Capital allocation, year by year

Xenon Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearXenon Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$69.5MFY2021: Shares issued $260KFY2021: Capital spending −$2.0M$260KFY2021FY2022: Operating cash flow −$101MFY2022: Shares issued $278MFY2022: Capital spending −$2.9M$278MFY2022FY2023: Operating cash flow −$151MFY2023: Shares issued $354MFY2023: Capital spending −$5.6M$354MFY2023FY2024: Operating cash flow −$181MFY2024: Shares issued $12.1MFY2024: Capital spending −$3.1M$12.1MFY2024FY2025: Operating cash flow −$279MFY2025: Shares issued $5.0MFY2025: Capital spending −$799K$5.0MFY2025
Over these 5 years operating cash flow totalled −$782M; the largest uses were operating cash flow ($782M) and capital spending ($14.4M). Cash-flow statements as filed.

Where the cash came from and went

Xenon Pharmaceuticals: sources (+) and uses (−) of cash, Q2 2026Xenon Pharmaceuticals: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$426MOther investing−$331MOperating cash flow−$95.4MCapital spending−$275KExchange rates$262KShares issued$26K
Xenon Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q2 2026Xenon Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$950MOther investing−$636MOperating cash flow−$338MCash drawn (+) / kept (−)$15.9MShares issued$9.3MCapital spending−$1.0MExchange rates$22K

From profit to cash

Xenon Pharmaceuticals: net income to operating cash flow, Q2 2026Xenon Pharmaceuticals: net income to operating cash flow, Q2 2026Net income−$111MDepreciation & amortization$558KStock-based pay$16.7MDeferred taxes−$1.9MPayables$5.7MPrepaid and other assets−$2.5MOther liabilities$41KOperating cash flow−$95.4M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$95.4M−$275K$26K$426M−$95.7M
Q1 2026−$88.9M−$133K$5.5M−$347M−$89.0M
Q4 2025−$81.5M−$318K$1.4M−$94.6M−$81.8M
Q3 2025−$71.8M−$281K$2.4M$30.9M−$72.0M
Q2 2025−$64.2M−$157K$65K−$18.7M−$64.4M
Q1 2025−$61.7M−$43K$1.2M$26.1M−$61.7M
Q4 2024−$54.4M−$783K$47K−$55.1M−$55.2M
Q3 2024−$49.7M−$590K—$49.1M−$50.3M

Xenon Pharmaceuticals: income statement and cash flow

Xenon Pharmaceuticals, Q1 2025: revenue $7.5M, operating margin -969.8%. The chart follows the revenue to costs, profit and cash.

Xenon Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.